Publication at First Faculty of Medicine, Faculty of Medicine in Hradec Králové |
2017
Abstract
Cobimetinib is a new MEK inhibitor, which - in combination therapy with vemurafenib - is a possible alternative to the usual treatment of advanced melanoma with BRAFV600 mutation. In randomised, double-blind, placebo controlled multicentre study, combination of cobimetinib and vemurafenib compared with placebo and vemurafenib in previously untreated patients with BRAFV600 mutant advanced melanoma significantly improved progression-free survival, overall survival and objective response rate, with manageable side effects.